From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K. Choueiri; Laurence Albiges; Michael B. Atkins; Ziad Bakouny; Gennady Bratslavsky; David A. Braun; Naomi B. Haas; John B.A.G. Haanen; A. Ari Hakimi; Michael A.S. Jewett; Eric Jonasch; William G. Kaelin; Payal Kapur; Chris Labaki; Bryan Lewis; David F. McDermott; Sumanta K. Pal; Kevin Pels; Susan Poteat; Thomas Powles; W. Kimryn Rathmell; Brian I. Rini; Sabina Signoretti; Nizar M. Tannir; Robert G. Uzzo; Hans J. Hammers

doi:10.1158/1078-0432.CCR-21-3238

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K. Choueiri, Laurence Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi B. Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett, Eric Jonasch, William G. Kaelin, Payal Kapur, Chris Labaki, Bryan Lewis, David F. McDermott, Sumanta K. Pal, Kevin Pels, Susan Poteat, Thomas PowlesW. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Hans J. Hammers

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

15 Citations (Scopus)

Résumé

The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.

langue originale	Anglais
Pages (de - à)	831-839
Nombre de pages	9
journal	Clinical Cancer Research
Volume	28
Numéro de publication	5
Les DOIs	https://doi.org/10.1158/1078-0432.CCR-21-3238
état	Publié - 1 mars 2022

Accès au document

10.1158/1078-0432.CCR-21-3238

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Choueiri, T. K., Albiges, L., Atkins, M. B., Bakouny, Z., Bratslavsky, G., Braun, D. A., Haas, N. B., Haanen, J. B. A. G., Hakimi, A. A., Jewett, M. A. S., Jonasch, E., Kaelin, W. G., Kapur, P., Labaki, C., Lewis, B., McDermott, D. F., Pal, S. K., Pels, K., Poteat, S., ... Hammers, H. J. (2022). From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 28(5), 831-839. https://doi.org/10.1158/1078-0432.CCR-21-3238

@article{02073fd2662347b7a9447c28cd941ba3,

title = "From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit",

abstract = "The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.",

author = "Choueiri, {Toni K.} and Laurence Albiges and Atkins, {Michael B.} and Ziad Bakouny and Gennady Bratslavsky and Braun, {David A.} and Haas, {Naomi B.} and Haanen, {John B.A.G.} and Hakimi, {A. Ari} and Jewett, {Michael A.S.} and Eric Jonasch and Kaelin, {William G.} and Payal Kapur and Chris Labaki and Bryan Lewis and McDermott, {David F.} and Pal, {Sumanta K.} and Kevin Pels and Susan Poteat and Thomas Powles and Rathmell, {W. Kimryn} and Rini, {Brian I.} and Sabina Signoretti and Tannir, {Nizar M.} and Uzzo, {Robert G.} and Hammers, {Hans J.}",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2022",

month = mar,

day = "1",

doi = "10.1158/1078-0432.CCR-21-3238",

language = "English",

volume = "28",

pages = "831--839",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "5",

}

Choueiri, TK, Albiges, L, Atkins, MB, Bakouny, Z, Bratslavsky, G, Braun, DA, Haas, NB, Haanen, JBAG, Hakimi, AA, Jewett, MAS, Jonasch, E, Kaelin, WG, Kapur, P, Labaki, C, Lewis, B, McDermott, DF, Pal, SK, Pels, K, Poteat, S, Powles, T, Rathmell, WK, Rini, BI, Signoretti, S, Tannir, NM, Uzzo, RG & Hammers, HJ 2022, 'From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit', Clinical Cancer Research, VOL. 28, Numéro 5, p. 831-839. https://doi.org/10.1158/1078-0432.CCR-21-3238

TY - JOUR

T1 - From Basic Science to Clinical Translation in Kidney Cancer

T2 - A Report from the Second Kidney Cancer Research Summit

AU - Choueiri, Toni K.

AU - Albiges, Laurence

AU - Atkins, Michael B.

AU - Bakouny, Ziad

AU - Bratslavsky, Gennady

AU - Braun, David A.

AU - Haas, Naomi B.

AU - Haanen, John B.A.G.

AU - Hakimi, A. Ari

AU - Jewett, Michael A.S.

AU - Jonasch, Eric

AU - Kaelin, William G.

AU - Kapur, Payal

AU - Labaki, Chris

AU - Lewis, Bryan

AU - McDermott, David F.

AU - Pal, Sumanta K.

AU - Pels, Kevin

AU - Poteat, Susan

AU - Powles, Thomas

AU - Rathmell, W. Kimryn

AU - Rini, Brian I.

AU - Signoretti, Sabina

AU - Tannir, Nizar M.

AU - Uzzo, Robert G.

AU - Hammers, Hans J.

PY - 2022/3/1

Y1 - 2022/3/1

N2 - The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.

AB - The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.

UR - http://www.scopus.com/inward/record.url?scp=85125735918&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-21-3238

DO - 10.1158/1078-0432.CCR-21-3238

M3 - Article

C2 - 34965942

AN - SCOPUS:85125735918

SN - 1078-0432

VL - 28

SP - 831

EP - 839

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 5

ER -